Glucose-dependent insulinotropic polypeptide (GIP).

Mol Metab · 2025 · PMC11931254 · PMID 40024571

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While the numerical weight loss seen with NNC0480-0389 did not reach statistical significance compared to placebo, two of the four tested doses of NNC0480-0389 in combination with semaglutide 2.4 mg resulted in significantly greater weight losses relative to semaglutide 2.4 mg alone; supporting a weight loss effect of the GIPRA.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.